BeOne Medicines (ONC) Depreciation & Amortization (CF) (2015 - 2026)

BeOne Medicines (ONC) has reported Depreciation & Amortization (CF) for 12 consecutive years, with $41.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) rose 25.42% year-over-year to $41.1 million; the TTM figure through Mar 2026 stood at $150.0 million (down 16.31% YoY), while the FY2025 annual figure was $141.7 million, down 17.51% from the prior year.
• Depreciation & Amortization (CF) grew to $41.1 million in Q1 2026 per ONC's latest filing, from $36.0 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $71.3 million in Q3 2024 and bottomed at $15.5 million in Q2 2022.
• Historically, Depreciation & Amortization (CF) has averaged $29.9 million across 5 years, with a median of $24.9 million in 2024.
• Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) soared 231.44% — and 2025, when it sank 47.7%.
• BeOne Medicines' Depreciation & Amortization (CF) stood at $18.0 million in 2022, then soared by 32.21% to $23.8 million in 2023, then soared by 110.95% to $50.2 million in 2024, then fell by 28.38% to $36.0 million in 2025, then rose by 14.34% to $41.1 million in 2026.
• Business Quant data shows ONC's Depreciation & Amortization (CF) at $41.1 million in Q1 2026, $36.0 million in Q4 2025, and $37.3 million in Q3 2025.